Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis

Ye, Qingjian; Cheng, Juan; Ye, Minjuan; Liu, Dong

doi:10.3802/jgo.2019.30.e5

Cited by 26 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were also confirmed in a recent systematic review and meta-analysis of 11 pooled studies conducted by Ye et al . [ 21 ] reported that pretreatment thrombocytosis was a significant negative predictor of both PFS and OS in women with EOC for all stages and degrees of differentiation. This is at variance to the work of Allensworth et al .…”

Section: Discussionmentioning

confidence: 99%

“…[ 20 ] A recent systematic review and meta-analysis conducted by Ye et al reported that pretreatment thrombocytosis was a significant negative predictor of both survival in women with epithelial ovarian cancer (EOC). [ 21 ] However, it is still not clearly understood whether prognosis in ovarian cancer patients is directly affected by the presence of a high level of platelets or if thrombocytosis is a surrogate for other prognostic indicators, such as advanced-stage disease, suboptimal cytoreduction, or even medical comorbidity. On this basis, the current study, therefore, investigated the impact of pretreatment thrombocytosis on progression-free survival (PFS) and overall survival (OS) in black Nigerian women with EOC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer

et al. 2020

View full text Add to dashboard Cite

Aims: This study was aimed at investigating the prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer (EOC) patients in Lagos, Nigeria. Methods: This was a retrospective cohort study involving the review of the clinical record of 72 patients with histologically confirmed EOC who were managed at the Lagos University Teaching Hospital, Lagos, Nigeria over a 7-year period from January 2010 to December 2016. Information on the sociodemographic data and platelet counts at diagnosis of EOC were retrieved from the patients’ medical records. Descriptive statistics were then computed for all baseline patients’ characteristics. Survival analyses were carried out using the Kaplan-Meier estimates. Multivariate analysis of these data was performed with the Cox proportional hazards model. Results: This study revealed that the prevalence of pretreatment thrombocytosis was 41.7% among the women with EOC. Fifty-three (73.6%) of the women had the advanced-stage disease (FIGO stage III-IV) while 52 (72.2%) had high-grade disease (II-III). The majority (66.7%) of the women had a serous histological type of EOC while 76.4% had documented recurrence. Pretreatment thrombocytosis was significantly associated with the women’s parity ( P = 0.009), serum carbohydrate antigen 125 levels ( P = 0.018), median progression-free survival (PFS) ( P < 0.001), 3-year median overall survival (OS) ( P < 0.001), type of primary treatment ( P = 0.002), extent of cytoreduction ( P < 0.001), presence of ascites ( P = 0.002), International Federation of Gynecology and Obstetrics (FIGO) stage ( P = 0.008), and histological type ( P = 0.011). Pretreatment thrombocytosis was negatively associated with PFS (hazard ratio [HR] = 0.25; 95% CI 0.83, 0.75; P = 0.014) and 3-year OS (HR = 0.03; 95% CI 0.03, 0.27; P = 0.002). Conclusions: The study suggests that pretreatment thrombocytosis may be a useful predictor of survivals in EOC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Numerous researches showed that platelet activation play an important part in cancer progression. Thrombocytosis is related to worse clinical outcome in patients with various cancers, including ovarian cancer, colorectal cancer, and pancreatic cancer 20–22 . The PDW that is one of the platelet indices not merely check platelet volume heterogeneity, but also reactive platelet activity.…”

Section: Discussionmentioning

confidence: 99%

Elevated preoperative platelet distribution width predicts poor prognosis in Esophageal Squamous Cell Carcinoma

Song

Wang

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Activated platelets play a multifaceted role in tumorigenesis and progression. Platelet distribution width (PDW) is generally applied platelet parameters from routine blood test. Preoperative PDW has been considered a prognostic factor in many cancers. Nevertheless, the prognostic value of PDW in esophageal squamous cell carcinoma (ESCC) remains unknown. The study aimed to investigate whether preoperative PDW could serve as a prognostic factor in patients with ESCC. A total of 495 patients with ESCC undergoing curative surgery were enrolled. The relationship between PDW and clinical features in ESCC was analyzed using chi-square tests. Receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value. Overall survival (OS) and disease-free survival (DFS) stratified by PDW were evaluated by Kaplan–Meier method and log-rank test. Univariate and multivariate Cox regression were used to evaluate the prognostic effect of PDW. Of the 495 patients, elevated PDW was observed in 241(48.7%) of the patients, respectively. An elevated PDW was correlated with depth of tumor (T stage, P = 0.031), nerve infiltration (P = 0.016), hospital time after operation (P = 0.020), platelet (P < 0.001), red cell distribution width (P < 0.001), and aspartate transaminase (P = 0.001). Moreover, elevated PDW (PDW ≥ 13.4 fL) predicted a worse OS and DFS in patients with ESCC (both P < 0.001). Multivariate analyses revealed that PDW was independently associated with OS (hazard ratios 1.194; 95% confidence interval 1.120–1.273; P < 0.001) and DFS (hazard ratios 2.562; 95% confidence interval 1.733–3.786; P < 0.001). Our findings indicated that elevated PDW could serve as an independent worse survival in ESCC.

show abstract

“…Thrombocytosis observed in oncology patients has been reported to entail a worse prognosis in a variety of solid tumours: colorectal, 6 , 7 breast, 8 lung, 6 , 9 renal, 6 , 10 cervical, 11 ovarian 12 and brain tumours. 13 Only meagre data are available in the literature on the relationship between thrombocytosis and prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

The Correlation Between Platelet Count and Survival in Prostate Cancer

Mezei¹,

Bőde²,

Tenke³

et al. 2022

RRU

View full text Add to dashboard Cite

Purpose A number of studies have confirmed that elevated platelet count accompanying various solid tumours is associated with worse survival. However, only meagre data are available on the relationship between thrombocytosis and survival in prostate cancer. Methods We conducted a retrospective analysis on clinical-pathological data accumulated from 316 patients during on average 51 months of follow-up after laparoscopic prostatectomy performed for prostate cancer. We analyzed the relationship between platelet count, risk factors, prostate-specific antigen (PSA) and cancer stage with use the Tumor, Node, Metastase system (TNM), as well as surgical margin, and prognosis. Results Thrombocytosis occurred in only one out of the 316 patients. The multivariate Cox proportional hazard model showed that preoperative PSA, risk group, preoperative haemoglobin level, and surgical margin status were significant, independent predictors of biochemical progression-free survival. By contrast, age at diagnosis and thrombocytosis had no such predictive value. Conclusion We could not demonstrate an association between elevated platelet count and worse survival in our study population of patients with prostate cancer.

show abstract

Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis

Cited by 26 publications

References 29 publications

Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer

Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer

Elevated preoperative platelet distribution width predicts poor prognosis in Esophageal Squamous Cell Carcinoma

The Correlation Between Platelet Count and Survival in Prostate Cancer

Contact Info

Product

Resources

About